NASDAQ: TNGXTango Therapeutics Inc Stock
$7.76-0.01 (-0.13%)
Updated Apr 24, 2024
TNGX Price
$7.76
Fair Value Price
-$6.32
Market Cap
$828.13M
52 Week Low
$2.47
52 Week High
$13.03
P/E
-7.19x
P/B
3.27x
P/S
25.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$36.53M
Earnings
-$101.74M
Gross Margin
100%
Operating Margin
-278.18%
Profit Margin
-278.5%
Debt to Equity
0.59
Operating Cash Flow
-$118M
Beta
1.04
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
TNGX Overview
Tango Therapeutics Incorporated is a biotechnology company that develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 to treat cancers with methylthioadenosine phosphorylase deletions. The company is also developing Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers, and Target 3 for STK11-mutant cancers. Tango Therapeutics was founded in 2017 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TNGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TNGX ($7.76) is overvalued by 222.83% relative to our estimate of its Fair Value price of -$6.32 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TNGX ($7.76) is not significantly undervalued (222.83%) relative to our estimate of its Fair Value price of -$6.32 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TNGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TNGX due diligence checks available for Premium users.
Be the first to know about important TNGX news, forecast changes, insider trades & much more!
TNGX News
Valuation
TNGX fair value
Fair Value of TNGX stock based on Discounted Cash Flow (DCF)
Price
$7.76
Fair Value
-$6.32
Undervalued by
222.83%
TNGX ($7.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TNGX ($7.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TNGX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TNGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.19x
Industry
15.69x
Market
41.27x
TNGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.27x
Industry
5.86x
TNGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TNGX's financial health
Profit margin
Revenue
$5.4M
Net Income
-$30.8M
Profit Margin
-566.4%
TNGX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TNGX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$402.6M
Liabilities
$149.5M
Debt to equity
0.59
TNGX's short-term assets ($346.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TNGX's short-term assets ($346.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TNGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$27.5M
Investing
$33.9M
Financing
$1.5M
TNGX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TNGX vs Biotech Stocks
Tango Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.